



Regulus Therapeutics Inc.  
Investor Relations Department  
10614 Science Center Dr  
San Diego, CA 92121  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: RGLS**

Last Trade:	1.27
Trade Time:	11:43 AM ET Oct 20, 2017
Change:	0.02 <span style="color: green;">↑</span> (+1.600%)
Day Range	1.16 - 1.28
52-Week Range	0.79 - 3.38
Volume	334,281

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

### Company Profile

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Regulus maintains its corporate headquarters in La Jolla, CA.

... [\(more\)](#)

### Stock Performance



### Press Releases [\[ View all \]](#)

- [Aug 30, 2017  
Regulus to Present at the 2017 Wells Fargo Healthcare Conference](#)
- [Aug 8, 2017  
Regulus to Present at the 2017 Webdush PacGrow Healthcare Conference](#)
- [Aug 1, 2017  
Regulus Reports Second Quarter 2017 Financial Results and Recent Events](#)
- [Jul 25, 2017  
Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares](#)
- [Jul 25, 2017  
Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017](#)

### Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- [Mar 3, 2017  
Annual Report \(10-K\)](#)
- [Apr 28, 2017  
Proxy Statement \(DEF 14A\)](#)
- [Aug 2, 2017  
Quarterly Report \(10-Q\)](#)
- [May 5, 2017  
Quarterly Report \(10-Q\)](#)
- [Nov 2, 2016  
Quarterly Report \(10-Q\)](#)